A carregar...
A new “FIX” for hemophilia B gene therapy
In this issue of Blood, Nair et al(1) demonstrate that AAV-directed gene therapy using a new bioengineered FIX transgene provides higher FIX activity and superior hemostatic efficacy than other FIX variants and may allow for lower and potentially safer vector doses in future human clinical trials.
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8160502/ https://ncbi.nlm.nih.gov/pubmed/34042982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2021011753 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|